Abstract
The wastewater viral activity level (WVAL) was developed by the United States Centers for Disease Control and Prevention (US CDC) as a standardized metric to aggregate SARS-CoV-2 wastewater data, enabling the assessment of infection levels and trends at state/territorial, regional and national scales. This approach also facilitates comparative analysis of SARS-CoV-2 prevalence across regions. In this study, we developed and evaluated graphical methods to integrate the WVAL metric into interpretable visualizations for public health decision-making. Preliminary analysis demonstrated that WVAL values correlated strongly with clinical case counts, supporting its role as a confirmatory epidemiological measure. The WVAL framework provided a linear quantification method, allowing for the comparison of regional variations in infection patterns. This study leveraged data from the Ontario Wastewater Surveillance Initiative (Ontario WSI), which included over 100 sampling sites across seven geographical regions. Weekly mean WVAL values were computed for each site and aggregated at regional and provincial levels. In total, 59 sites contributed to the provincial WVAL calculation. The computational aggregation method followed the US CDC’s WVAL approach and was generally comparable to the Public Health Ontario (PHO) aggregation method, with the notable improvement of incorporating a linear level scale. Overall, this study demonstrated that WVAL effectively quantified SARS-CoV-2 differences at a public health regional scale. The WVAL metric proved to be a robust epidemiological tool, complementing other surveillance measures to support public health decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Ontario Wastewater Surveillance Initiative of the Ontario Ministry of the Environment, Conservation and Parks (MECP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
